Table 1.
Patient characteristics
| All Patients (n=105) | No Hemodialysis-Induced Regional LV Dysfunction (n=76) | Hemodialysis-Induced Regional LV Dysfunction (n=29) | P Value | |
|---|---|---|---|---|
| Median age in years (IQR) | 66 (51–75) | 64 (50–75) | 69 (58–78) | 0.18 |
| Male sex (n) | 68 (64.8%) | 45 (59.2%) | 23 (79.3%) | 0.05 |
| Median dialysis vintage in months (IQR) | 21.4 (7.8–48.5) | 24 (8.3–48.3) | 18.4 (5.5–49.7) | 0.69 |
| Diabetes (n) | 23 (21.9%) | 19 (25.0%) | 4 (13.8%) | 0.28 |
| Hypertension (n) | 84 (80.0%) | 61 (80.3%) | 23 (79.3%) | 0.95 |
| Cardiovascular history (n) | 23 (21.9%) | 15 (19.7%) | 8 (27.6%) | 0.39 |
| Median BMI (kg/m2; IQR) | 25.2 (23.0–28.1) | 25.2 (22.6–28.3) | 25.2 (23.2–27.8) | 0.88 |
| Primary renal disease (n) | ||||
| Hypertension | 17 (16.2%) | 12 (15.8%) | 5 (17.2%) | 0.86 |
| Diabetes | 13 (12.4%) | 11 (14.5%) | 2 (6.9%) | 0.29 |
| ADPKD | 14 (13.3%) | 10 (13.6%) | 4 (13.8%) | 0.93 |
| FSGS | 10 (9.5%) | 8 (10.5%) | 2 (6.9%) | 0.57 |
| IgA nephropathy | 4 (3.8%) | 4 (5.3%) | 0 | 0.21 |
| Chronic pyelonephritis | 1 (1.0%) | 1 (1.3%) | 0 | 0.54 |
| Glomerulonephritis | 13 (12.4%) | 10 (13.2%) | 3 (10.3%) | 0.70 |
| Other diagnoses | 16 (15.2%) | 10 (13.2%) | 6 (20.6%) | 0.21 |
| Unknown | 17 (16.2%) | 10 (13.2%) | 7 (24.1%) | 0.17 |
| Medication (n) | ||||
| Aspirin | 57 (54.3%) | 46 (60.5%) | 11 (37.9%) | 0.04 |
| CCB | 14 (13.3%) | 12 (15.8%) | 2 (6.9%) | 0.23 |
| β-Blocker | 60 (57.1%) | 45 (59.2%) | 15 (51.7%) | 0.49 |
| ACE inhibitor | 10 (9.5%) | 8 (10.5%) | 2 (6.9%) | 0.57 |
| ARB | 14 (13.3%) | 10 (13.2%) | 4 (13.8%) | 0.34 |
| Statin | 20 (19.1%) | 14 (18.4%) | 6 (20.7%) | 0.79 |
| Median SGA (IQR) | 6 (6–7) | 6 (6–7) | 6 (5–7) | 0.77 |
| Hematocrit (mean ± SD) | 35.0±3.7 | 35.1±4.0 | 34.6±3.0 | 0.53 |
| Median albumin (g/L; IQR) | 39 (37–41) | 39 (37–42) | 39 (37–41) | 0.64 |
| Median phosphate (mmol/L; IQR) | 1.7 (1.3–1.9) | 1.7 (1.3–2.0) | 1.6 (1.4–1.9) | 0.92 |
| Median Kt/V (IQR) | 4.3 (3.8–4.7) | 4.3 (3.8–4.7) | 4.0 (3.9–4.5) | 0.36 |
| Ultrafiltration volume (L; mean ± SD) | 2.6±0.8 | 2.5±0.7 | 2.60±0.9 | 0.83 |
| Ultrafiltration rate (ml/kg per hour; mean ± SD) | 8.5±2.6 | 8.6±2.5 | 8.3±3.0 | 0.59 |
| LV mass index (g/m2; mean ± SD) | 93.3±26.0 | 89.9±24.6 | 101.7±27.9 | 0.05 |
| LVH (n) | 25 (23.8%) | 19 (25%) | 6 (20.7%) | 0.64 |
| Median predialysis WMSI (IQR) | 1.00 (1.00–1.13) | 1.00 (1.00–1.03) | 1.21 (1.06–1.44) | <0.001 |
| Predialysis LVEF (mean ± SD) | 50.0%±10.4% | 51.8%±9.5% | 45.3%±10.4% | 0.008 |
LV, left ventricular; IQR, interquartile range; BMI, body mass index; ADPKD, adult dominant polycystic kidney disease; FSGS, focal segmental glomerulosclerosis; CCB, calcium channel blocker; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; SGA, subjective global assessment; LVH, LV hypertrophy; WMSI, wall motion score index; LVEF, LV ejection fraction.